Literature DB >> 21894641

Structural characteristics correlate with immune responses induced by HIV envelope glycoprotein vaccines.

Victoria A Sharma1, Elaine Kan, Yide Sun, Ying Lian, Jimna Cisto, Verna Frasca, Susan Hilt, Leonidas Stamatatos, John J Donnelly, Jeffrey B Ulmer, Susan W Barnett, Indresh K Srivastava.   

Abstract

HIV envelope glycoprotein (Env) is the target for inducing neutralizing antibodies. Env is present on the virus surface as a trimer, and, upon binding to CD4, a cascade of events leads to structural rearrangement exposing the co-receptor binding site and entry into the CD4+ host target cells. We have designed monomeric and trimeric Env constructs with and without deletion of the variable loop 2 (ΔV2) from SF162, a subtype B primary isolate, and performed biophysical, biochemical and immunological studies to establish a potential structure–functional relationship. We expressed these Envs in CHO cells, purified the proteins to homogeneity and performed biophysical studies to define the binding properties to CD4, structural characteristics and exposure of epitopes recognized by b12 and CD4i mAb (17B) on both full-length and mutant HIV Env proteins. Parameters evaluated include oligomerization state, number and affinity of CD4 binding sites, enthalpy and entropy of the Env–CD4 interaction and affinity for b12 and 17b mAbs. We observed one CD4 binding site per monomer and three active CD4 binding sites per trimer. A40-fold difference in affinity of the gp120 monomer vs. the o-gp140 trimer towards CD4 was observed (Kd = 58 nM and 1.5 nM, respectively),whereas only a 2-fold difference was observed for the V2 deleted Envs (Kd of gp120ΔV2 = 19 nM, Kd of o-gp140DV2 = 9.3 nM). Monomers had 3-fold higher affinity to the mAb 17b and at least 3-fold weaker affinity to b12 compared to trimers, with gp120DV2 having the weakest affinity for b12 (Kd = 446 nM). Affinity of CD4 binding correlated with proportion of the antibodies induced against the conformational epitopes by the corresponding Envs, and changes in mAb binding correlated with the induction of antibodies directed against linear epitopes. Furthermore,biophysical analysis reveals that the V2 deletion has broad structural implications in the monomer not shared by the trimer, and these changes are reflected in the quality of the immune responses induced in rabbits. These data suggest that biophysical characteristics of HIV Env, such as affinity for CD4, and exposure of important neutralizing epitopes, such as those recognized by b12 mAb, may be important predictors of its in vivo efficacy and may serve as important surrogate markers for screening Env structures as potential vaccine candidates. ©2006 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 21894641     DOI: 10.1016/j.virol.2006.04.030

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  12 in total

1.  Chemical optimization of macrocyclic HIV-1 inactivators for improving potency and increasing the structural diversity at the triazole ring.

Authors:  Adel A Rashad; Kriti Acharya; Ann Haftl; Rachna Aneja; Alexej Dick; Andrew P Holmes; Irwin Chaiken
Journal:  Org Biomol Chem       Date:  2017-09-26       Impact factor: 3.876

2.  Slow Receptor Binding of the Noncytopathic HIV-2UC1 Envs Is Balanced by Long-Lived Activation State and Efficient Fusion Activity.

Authors:  Miranda Harris; Sneha Ratnapriya; Angela Chov; Héctor Cervera; Alisha Block; Christopher Gu; Nathaniel Talledge; Louis M Mansky; Joseph Sodroski; Alon Herschhorn
Journal:  Cell Rep       Date:  2020-06-09       Impact factor: 9.423

3.  Quaternary structures of HIV Env immunogen exhibit conformational vicissitudes and interface diminution elicited by ligand binding.

Authors:  Carlos G Moscoso; Yide Sun; Selina Poon; Li Xing; Elaine Kan; Loïc Martin; Dominik Green; Frank Lin; Anders G Vahlne; Susan Barnett; Indresh Srivastava; R Holland Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-28       Impact factor: 11.205

4.  Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research.

Authors:  Lindsay Wieczorek; Shelly J Krebs; Vaniambadi Kalyanaraman; Stephen Whitney; Sodsai Tovanabutra; Carlos G Moscoso; Eric Sanders-Buell; Constance Williams; Bonnie Slike; Sebastian Molnar; Vincent Dussupt; S Munir Alam; Agnes-Laurence Chenine; Tina Tong; Edgar L Hill; Hua-Xin Liao; Michael Hoelscher; Leonard Maboko; Susan Zolla-Pazner; Barton F Haynes; Michael Pensiero; Francine McCutchan; Shawyon Malek-Salehi; R Holland Cheng; Merlin L Robb; Thomas VanCott; Nelson L Michael; Mary A Marovich; Carl R Alving; Gary R Matyas; Mangala Rao; Victoria R Polonis
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

5.  Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant.

Authors:  Susan W Barnett; Brian Burke; Yide Sun; Elaine Kan; Harold Legg; Ying Lian; Kristen Bost; Fengmin Zhou; Amanda Goodsell; Jan Zur Megede; John Polo; John Donnelly; Jeffrey Ulmer; Gillis R Otten; Christopher J Miller; Michael Vajdy; Indresh K Srivastava
Journal:  J Virol       Date:  2010-04-14       Impact factor: 5.103

6.  Analysis of the disulfide bond arrangement of the HIV-1 envelope protein CON-S gp140 ΔCFI shows variability in the V1 and V2 regions.

Authors:  Eden P Go; Ying Zhang; Sushma Menon; Heather Desaire
Journal:  J Proteome Res       Date:  2010-12-30       Impact factor: 4.466

7.  Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes.

Authors:  Catherine A Blish; D Noah Sather; George Sellhorn; Leonidas Stamatatos; Yide Sun; Indresh Srivastava; Susan W Barnett; Brad Cleveland; Julie Overbaugh; Shiu-lok Hu
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

8.  Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody.

Authors:  Per Johan Klasse
Journal:  Virology       Date:  2007-09-07       Impact factor: 3.616

9.  Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein.

Authors:  Sean X Du; Rebecca J Idiart; Ellaine B Mariano; Helen Chen; Peifeng Jiang; Li Xu; Kristin M Ostrow; Terri Wrin; Pham Phung; James M Binley; Christos J Petropoulos; John A Ballantyne; Robert G Whalen
Journal:  Virology       Date:  2009-10-08       Impact factor: 3.616

10.  Neutralizing antibody responses to subtype B and C adjuvanted HIV envelope protein vaccination in rabbits.

Authors:  Brian Burke; Victor Raúl Gómez-Román; Ying Lian; Yide Sun; Elaine Kan; Jeffrey Ulmer; Indresh K Srivastava; Susan W Barnett
Journal:  Virology       Date:  2009-02-27       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.